Full-Time

Regulatory Affairs Director

Inflammation and Rare Disease

Updated on 8/13/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$189.6k - $256.6k/yr

+ Annual bonus + Stock-based long-term incentives

Remote in USA

Remote

Bachelor's, Master's, PhD

Category
Legal & Compliance (1)

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and 4 years of regulatory experience in biotechnology or science, or a master's degree and 7 years of regulatory experience in biotechnology or science, or a bachelor's degree and 9 years of regulatory experience in biotechnology or science.
Responsibilities
  • Develop and execute the global regulatory product strategy.
  • Lead Global Regulatory Teams.
  • Represent Regulatory on the product team and other key commercialization governance bodies.
  • Develop the Global Regulatory Strategic Plan and provide regulatory input into the product’s Global Strategic Plan.
  • Obtain input from Global Regulatory Team members to develop a global regulatory strategy supporting product development, registration, and lifecycle maintenance, and identify and communicate regulatory risks.
  • Represent Global Regulatory Affairs on the product team.
  • Develop registration strategies and plans aimed at achieving regulatory approval and product labeling.
  • Provide regulatory direction in developing the core data sheet to align commercial objectives with available and expected scientific data, regulatory guidance, and precedent.
  • Lead the planning and implementation of global regulatory filings, including clinical trial applications, marketing applications, label extensions, and chemistry, manufacturing, and controls changes.
  • Ensure consistency of evidence-based global product communication, including regulatory submission documents.
  • Monitor and assess the impact of relevant global regulations, guidance, and the current regulatory environment.
  • Ensure that guidance on regulatory mechanisms is assessed and incorporated into the global regulatory strategy, including expediting first-in-human studies, Orphan Drug, Fast Track, conditional or accelerated approval, compassionate use, and pediatric plans.
  • Communicate well-defined and successful regulatory strategies throughout the organization so expectations are understood.
  • Ensure effective regulatory agency communications by leading core regulatory and cross-functional teams, including Global Regulatory Teams and filing teams.
  • Attend key regulatory agency meetings that could impact the global product strategy.
  • Represent Amgen Regulatory on external partnership teams at the product level.
Desired Qualifications
  • Ability to lead and build effective teams.
  • Strong oral and written communication skills.
  • Ability to understand and communicate scientific and clinical information.
  • Ability to anticipate and mitigate future strategic issues and uncertainties.
  • Ability to resolve conflicts and develop a course of action.
  • Cultural awareness and sensitivity to achieve global results.
  • Planning and organizing abilities.
  • Ability to prioritize and manage multiple activities.
  • Ability to make complex decisions and solve problems.
  • Ability to deal with ambiguity.
  • Negotiation skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $39.4 billion.
  • Repatha, Evenity, and Uplizna grew 37%, 38%, and 90% in Q2 2026.
  • Colorado’s Enbrel price cap stayed blocked on July 1, 2026, preserving legacy cash flows.

What critics are saying

  • FDA sought Tavneos withdrawal in April 2026; approval integrity is under attack.
  • Prolia and Xgeva fell 32% in Q2 2026 as biosimilars squeeze margins.
  • If Tavneos disappears, Amgen loses $500 million annual sales and credibility with regulators.

What makes Amgen unique

  • Repatha has outcomes data across primary and secondary prevention, rare in PCSK9s.
  • Amgen’s six growth drivers delivered 26% growth and nearly 70% of Q2 sales.
  • Hyderabad center opens in 2027, expanding seven-lab R&D with data-driven discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.

Yahoo Finance
Jul 7th, 2026
Amgen wins Enbrel price cap reprieve as Class II recalls raise quality concerns

Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.